PCPC: 'Double Fees' For Cosmetic-Drug Products Are Regulatory Reform Concern
This article was originally published in The Rose Sheet
Cosmetic products containing OTC drug ingredients – such as acne-fighting agents and UV filters in skin-care and makeup items, fluoride in toothpaste and dandruff medication in shampoo – could be subject to multiple fees if FDA's concept for generating OTC monograph program funding were to become a reality along with the Personal Care Products Safety Act.
You may also be interested in...
In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.
Canadian firm’s eye health supplements Occuvite and PreserVision remain top sellers, with ReNu and Biotrue contact lens solutions and Lumify eye drops and skin care line rounding out its top 10 revenue generators.
Precision Patient Outcomes' compliance costs from settlement with FTC “are not onerous,” says New Civil Liberties Alliance attorney John Vecchione. Settlement requires firm to notify customers and resellers about lawsuit and preserve all scientific evidence for health claims made for its products.